Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Glaxo SmithKline

- PMLiVE

Intelligent Commercialization™ across the pharma lifecycle

Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

Inizio

- PMLiVE

Four steps to a smarter congress strategy: A practical guidebook

This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Inizio

- PMLiVE

Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...

Genesis Research Group

- PMLiVE

Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer

More than 186,000 men are diagnosed each year with mHSPC globally

- PMLiVE

AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo

Rinvoq is the first and only systemic medication approved in the EU for NSV

- PMLiVE

Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies

Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis

- PMLiVE

What do patient stories actually teach us?

How do we translate individual experiences into support that helps others and create support that feels personal but remains relevant to many?

Mednet

- PMLiVE

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize...

Inizio

- PMLiVE

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

Inizio

- PMLiVE

Ipsen to acquire Memo Therapeutics in deal worth more than €700m

The deal expands the company’s rare disease portfolio

- PMLiVE

Vertex to acquire Crinetics in deal worth around $10bn

The deal includes an approved treatment for acromegaly and other pipeline candidates

- PMLiVE

Novartis to acquire Myricx Bio in deal worth $1.5bn

Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links